SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of
the Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported) September 17, 2002
INCARA PHARMACEUTICALS CORPORATION
---------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware
----------------------------------------------
(State or other jurisdiction of incorporation)
0-27410 56-1924222
------------------------------- ---------------------------------------
(Commission File Number) (I.R.S. Employer Identification Number)
P.O. Box 14287
79 T.W. Alexander Drive
4401 Research Commons, Suite 200
Research Triangle Park, NC 27709
--------------------------------
(Address of principal executive office) (Zip Code)
Registrant's telephone number, including area code 919-558-8688
---------------------------
This Report contains, in addition to historical information, statements
by us with respect to expectations about our business and future results, which
are "forward-looking" statements under the Private Securities Litigation Reform
Act of 1995. These statements and other statements made elsewhere by us or our
representatives, which are identified or qualified by words such as "likely,"
"will," "suggests," "expects," "might," "believe," "could," "should," "may,"
"estimates," "potential," "predict," "continue," "would," "anticipates" or
"plans," or similar expressions, are based on a number of assumptions that are
subject to risks and uncertainties. Actual results could differ materially from
those currently anticipated or suggested due to a number of factors, including
those set forth herein, those set forth in our Annual Report on Form 10-K and in
our other SEC filings, and including risks relating to uncertainties relating to
clinical trials, the need for additional funds, the failure to satisfy the
listing requirements of the Nasdaq Stock market, dependence on collaborative
partners, the early stage of products under development and regulatory reviews
and competition. All forward-looking statements are based on information
available as of the date hereof, and we do not assume any obligation to update
such forward-looking statements.
Item 5. Other Events and Regulation FD Disclosure
On September 17, 2002, Incara Pharmaceuticals Corporation announced the
results of its clinical trial for deligoparin. The press release announcing this
event is attached.
Item 7. Financial Statements and Exhibits
(a) Exhibits
Exhibit 99.1 Press release issued September 17, 2002
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INCARA PHARMACEUTICALS CORPORATION
Date: September 17, 2002 By:
/s/ Richard W. Reichow
--------------------------------------------
Richard W. Reichow, Executive Vice
President, Chief Financial Officer and
Treasurer (Principal Financial and
Accounting Officer)